MDWD Stock Overview
A biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
MediWound Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$19.50 |
| 52 Week High | US$24.00 |
| 52 Week Low | US$11.90 |
| Beta | 0.81 |
| 1 Month Change | 13.54% |
| 3 Month Change | 12.81% |
| 1 Year Change | 60.63% |
| 3 Year Change | 21.12% |
| 5 Year Change | -6.20% |
| Change since IPO | -83.87% |
Recent News & Updates
MediWound Ltd.'s (NASDAQ:MDWD) P/S Still Appears To Be Reasonable
Jan 09
Earnings Update: MediWound Ltd. (NASDAQ:MDWD) Just Reported And Analysts Are Trimming Their Forecasts
Nov 29MediWound Is A Healthy Investment
Oct 29Recent updates
MediWound Ltd.'s (NASDAQ:MDWD) P/S Still Appears To Be Reasonable
Jan 09Earnings Update: MediWound Ltd. (NASDAQ:MDWD) Just Reported And Analysts Are Trimming Their Forecasts
Nov 29MediWound Is A Healthy Investment
Oct 29Market Participants Recognise MediWound Ltd.'s (NASDAQ:MDWD) Revenues Pushing Shares 43% Higher
Jul 23Analysts Have Made A Financial Statement On MediWound Ltd.'s (NASDAQ:MDWD) First-Quarter Report
Jun 01Revenues Tell The Story For MediWound Ltd. (NASDAQ:MDWD) As Its Stock Soars 25%
May 07We're Hopeful That MediWound (NASDAQ:MDWD) Will Use Its Cash Wisely
Feb 28Optimistic Investors Push MediWound Ltd. (NASDAQ:MDWD) Shares Up 26% But Growth Is Lacking
Feb 01MediWound Ltd.'s (NASDAQ:MDWD) 26% Share Price Surge Not Quite Adding Up
Dec 18MediWound Ltd. (NASDAQ:MDWD) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected
Sep 29MediWound's NexoBrid for thermal burns in children gets EMA review
Sep 20Need To Know: Analysts Just Made A Substantial Cut To Their MediWound Ltd. (NASDAQ:MDWD) Estimates
Aug 11MediWound GAAP EPS of -$0.13 misses by $0.03, revenue of $4.67M misses by $0.61M
Aug 09MediWound refiling for NexoBrid to treat severe thermal burns gets FDA review
Aug 03MediWound adds 13% after favorable data for ulcer candidate
Jul 07MediWound taps Tzvi Palash as COO
Jun 30Is MediWound (NASDAQ:MDWD) In A Good Position To Deliver On Growth Plans?
Jun 24Here's Why We're Watching MediWound's (NASDAQ:MDWD) Cash Burn Situation
Dec 07Shareholder Returns
| MDWD | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -1.9% | 1.3% | 0.6% |
| 1Y | 60.6% | 1.2% | 22.4% |
Return vs Industry: MDWD exceeded the US Pharmaceuticals industry which returned 1.2% over the past year.
Return vs Market: MDWD exceeded the US Market which returned 22.4% over the past year.
Price Volatility
| MDWD volatility | |
|---|---|
| MDWD Average Weekly Movement | 7.5% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: MDWD has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MDWD's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 100 | Ofer Gonen | www.mediwound.com |
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma.
MediWound Ltd. Fundamentals Summary
| MDWD fundamental statistics | |
|---|---|
| Market cap | US$219.36m |
| Earnings (TTM) | -US$28.06m |
| Revenue (TTM) | US$19.72m |
10.7x
P/S Ratio-7.5x
P/E RatioIs MDWD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDWD income statement (TTM) | |
|---|---|
| Revenue | US$19.72m |
| Cost of Revenue | US$17.27m |
| Gross Profit | US$2.45m |
| Other Expenses | US$30.51m |
| Earnings | -US$28.06m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.60 |
| Gross Margin | 12.42% |
| Net Profit Margin | -142.29% |
| Debt/Equity Ratio | 0% |
How did MDWD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/06 01:00 |
| End of Day Share Price | 2025/02/06 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MediWound Ltd. is covered by 14 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Maris | BMO Capital Markets Equity Research |
| Jason Wittes | Brean Capital |
| Michael Gorman | BTIG |